Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Smith & Nephew Snats ( (SNN) ) has provided an announcement.
On August 27, 2025, Smith & Nephew plc announced the granting of performance and restricted share awards to Ajay Dhankhar, the Chief Corporate Strategy & Development Officer, under the Global Share Plan 2020 and Restricted Share Plan 2024. These awards, which are based on the company’s share price on the London Stock Exchange, are part of the company’s incentive strategy to align managerial interests with shareholder value and ensure long-term commitment from key personnel.
The most recent analyst rating on (SNN) stock is a Buy with a $41.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
Smith & Nephew Snats’ strong financial performance and positive earnings call are the most significant factors driving the score. The stock’s bullish technical indicators are tempered by overbought signals, and the valuation suggests it may be overvalued. Despite challenges in emerging markets and potential tariff impacts, the company’s strategic initiatives and share buyback plan reflect confidence in sustaining growth.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company based in Watford, England. The company specializes in advanced wound management, orthopedics, and sports medicine, focusing on providing innovative medical solutions to improve patient outcomes.
Average Trading Volume: 963,098
Technical Sentiment Signal: Buy
Current Market Cap: $16.19B
Learn more about SNN stock on TipRanks’ Stock Analysis page.